Argenica Therapeutics (ASX: AGN) has established a new Clinical Advisory Committee (CAC) to support the advancement of its Phase 2b trial for ARG-007 in acute ischaemic stroke.
This committee is designed to maximise the probability of clinical success as the programme progresses into later-stage development.
The CAC's remit includes supporting the optimisation of the trial design, specifically focusing on endpoints, patient selection, and dosing strategy.
The committee brings together internationally recognised experts in stroke neurology, neurointervention, neuroimaging, and neuroprotectant drug development.
Prominent members include Professor Geoffrey Donnan and Professor Jeffrey Saver, along with a consumer representative, Mr Tony Rolfe, with non-executive Director Dr Mark Etherton to also support the CAC.
ARG-007 Stroke Development Context
This strategic move follows previous advancements in the ARG-007 development programme.
Final results from the Phase 2 SEANCON trial for ARG-007 in acute ischaemic stroke patients undergoing endovascular thrombectomy were presented at the 2026 European Stroke Organisation Conference (ESOC) in May 2026.
Previous pre-clinical and clinical studies have also provided important context for ARG-007.
In December 2025, Argenica confirmed that ARG-007 did not interfere with the standard clot-dissolving agent tenecteplase.
Furthermore, an independent pre-clinical study in November 2025 validated the efficacy and dosing of ARG-007 for ischaemic stroke.
Financial Position and Funding
Argenica's financial position has been supported by a recent $3.97 million cash rebate from Australia’s R&D Tax Incentive Programme for FY25.
This rebate, received in March 2026, boosted the company's pro-forma cash balance to $9.0 million as at 31 December 2025.
However, the half-year results for the period ended 31 December 2025 indicated an increased cash burn.
Net operating cash outflows rose to $5,514,842, partly due to timing differences in the recognition and receipt of the R&D tax incentive in that specific period.
Regulatory Progress and Milestones
In February 2026, Argenica received a full product-specific paediatric waiver from the European Medicines Agency (EMA) for ARG-007 in paediatric acute ischaemic stroke.
This waiver means no paediatric clinical studies are required for children from birth to under 18 years, significantly streamlining the European regulatory pathway for the drug in adult acute ischaemic stroke.
The company's Phase 2 SEANCON trial results were accepted for both an oral presentation and as a Best Poster Finalist at the 2026 ESOC, highlighting the scientific quality of the data.
Strategic Steps for Clinical Advancement
Argenica Therapeutics is bolstering its Phase 2b trial design for ARG-007 through an expert advisory committee, while recent regulatory progress, including an EMA paediatric waiver, de-risks its European pathway.
The company's financial position, while strengthened by an R&D tax rebate, remains under observation due to elevated cash burn and timing-related receipt of incentives.
"The Committee brings deep expertise in moderate-to-severe stroke, imaging-based patient selection and late-stage clinical development, which will be critical in optimising trial design and execution," managing director Dr Liz Dallimore said.
"We are focused on maximising the probability of success as we progress ARG-007 towards the next stage of development.”
